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Abstract
Breast cancer is a diverse and complex disease that remains one of the leading causes of death 
among women. Novel, outside-of-the-box imaging and treatment methods are needed to 
supplement currently available technologies. In this study, we present evidence for the intracellular 
delivery and ultrasound-stimulated activation of folate receptor (FR)-targeted phase-change 
contrast agents (PCCAs) in MDA-MB-231 and MCF-7 breast cancer cells in vitro. PCCAs are 
lipid-coated, perfluorocarbon-filled particles formulated as nanoscale liquid droplets capable of 
vaporization into gaseous microbubbles for imaging or therapy. Cells were incubated with 1:1 
decafluorobutane (DFB) / octafluoropropane (OFP) PCCAs for 1 hour, imaged via confocal 
microscopy, exposed to ultrasound (9 MHz, MI = 1.0 or 1.5), and imaged again after insonation. 
FR-targeted PCCAs were observed intracellularly in both cell lines, but uptake was significantly 
greater (p < 0.001) in MDA-MB-231 cells (93.0% internalization at MI = 1.0, 79.5% at MI = 1.5) 
than MCF-7 cells (42.4% internalization at MI = 1.0, 35.7% at MI = 1.5). Folate incorporation 
increased the frequency of intracellular PCCA detection 45-fold for MDA-MB-231 cells and 7-
fold for MCF-7 cells, relative to untargeted PCCAs. Intracellularly activated PCCAs ranged from 
500 nm to 6 microns (IQR = 800 nm – 1.5 microns) with a mean diameter of 1.15 ± 0.59 (SD) 
microns. The work presented herein demonstrates the feasibility of PCCA intracellular delivery 
and activation using breast cancer cells, illuminating a new platform toward intracellular imaging 
or therapeutic delivery with ultrasound.
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1. Introduction
For women in the United States, breast cancer is the most commonly diagnosed cancer and 
second leading cause of cancer-related death [1]. With an estimated 1.38 million new breast 
cancer cases and 458,000 deaths per year worldwide [2], new and unique diagnostic and 
therapeutic tools are vital for slowing the progression and mortality of this disease.
Ultrasound (US) has been utilized for a broad range of applications in tumor imaging [3, 4, 
5, 6, 7] as well as drug and gene delivery [8, 9, 10, 40, 41]. Compared to other imaging 
paradigms, ultrasound is particularly advantageous as a noninvasive and nonionizing 
modality. Furthermore, ultrasound is portable and inexpensive, making it well suited for the 
rapidly evolving state of health care in the 21st century.
Microbubble contrast agents have been investigated for ultrasound imaging of 
atherosclerosis [11], tumor angiogenesis [12], and other applications of intravascular tumor 
imaging [5, 7, 13]. Gas-filled microbubbles (MBs) provide high imaging contrast relative to 
tissue, yet they are restricted to the vasculature by their size (typically 1 – 10 microns). This 
size limitation can be circumvented using nanoscale phase-change contrast agents (PCCAs), 
which refers to liquid perfluorocarbon droplets capable of shifting phases into gaseous 
microbubbles via acoustic droplet vaporization [14]. The PCCA platform is unique in that 
nanodroplets (50 – 700 nm) can be formulated small enough to potentially extravasate into 
cancer tissue, target specific biomarkers, and then undergo receptor-mediated endocytosis 
for intracellular nanoparticle delivery. The application of ultrasound can then trigger 
acoustic droplet vaporization of intracellular nanodroplets into gaseous microbubbles for 
imaging or therapy (Figure 1).
The ultrasound PCCA cancer-imaging concept is dependent upon the “leaky” vasculature of 
tumor tissue. In normal tissue, the maximum particle size for extravasation from the 
vasculature is roughly 10 nm, while nanoparticles up to 600 nm can escape through the 
porous tumor endothelium [15]. Tumor vasculature can be highly angiogenic, with abnormal 
blood vessels characterized by uneven diameter, excessive branching and shunts, and high 
permeability [16]. The enhanced permeability and retention (EPR) effect facilitates 
increased accumulation of nanoparticles in tumor tissue, and this passive tumor targeting 
mechanism is optimized for nanoparticles sized 50 – 250 nm [17]. Another advantage of the 
PCCA platform is the fact that perfluorocarbon nanodroplets can persist in circulation for 
significantly longer than microbubbles [18], thus enhancing the likelihood of extravasation 
and cellular targeting.
Our PCCAs are composed of a perfluorocarbon (PFC) core encapsulated by a lipid 
membrane, to which ligands can be attached for targeted delivery. In this study, the PFC core 
was a 1:1 mixture of decafluorobutane (DFB, C4F10, BP = −2 °C) and octafluoropropane 
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(OFP, C3F8, BP = −37 °C). When isolated in the bulk phase, these low-boiling 
perfluorocarbons vaporize well below physiological temperatures. However, when 
encapsulated at the micro- and nanoscale, PCCAs based on these perfluorocarbons exhibit 
thermal vaporization thresholds as much as 70 °C higher than the bulk boiling point due to 
the thermodynamic limits of superheat and additional Laplace pressure at these small sizes 
[19, 20].
PCCA-based ultrasound imaging relies upon the application of acoustic energy to activate 
nanodroplets into microbubbles. Under FDA ultrasound guidelines, the maximum 
mechanical index (MI) permitted clinically is 1.9. However, this does not necessarily imply 
that the clinical use of PCCAs will also be permitted at a maximum of 1.9. Indeed, the 
guidelines for the use of Definity™ microbubbles recommends a mechanical index less than 
0.8 in order to prevent microbubble cavitation [21]. Currently, there are no clinical care 
guidelines surrounding use of PCCAs, as they are not clinically approved agents. 
Nonetheless, our approach to generating droplets by condensing microbubbles has some 
unique strategic advantages that we believe will aid clinical translation – that droplets are 
formed from the same constitutive components used for clinically approved microbubbles. 
Before PCCAs can be used clinically, there are still a range of studies required on 
biodistribution, bioeffects upon activation, and dose tolerance.
Over the past few years, growing interest in PCCAs has launched efforts into understanding 
the underlying physics and acoustic characteristics of the agents [22]. Pre-clinical studies in 
large animals (i.e. porcine) have shown that, under limited frequencies and mechanical 
indices, vaporization and imaging with PCCAs does not seem to produce adverse effects 
[23]. However, there still needs to be an extensive and systematic treatise on PCCA safety 
and bioeffects over a range of MIs, investigating both the role of frequency and pressure 
across the entire diagnostic range.
Acoustic droplet vaporization of perfluorocarbon PCCAs has been studied using mechanical 
indices greater than 0.4 and ultrasound frequencies ranging from 5 – 40 MHz [19, 24, 25, 
26, 27, 28]. In general, as the boiling point of a perfluorocarbon increases, more acoustic 
energy is required for vaporization. This introduces a trade-off between nanodroplet thermal 
stability and sensitivity to acoustic droplet vaporization. In this study, we applied ultrasound 
at 9 MHz with a mechanical index of 1.0 or 1.5. Previous work has demonstrated that 1:1 
DFB/OFP PCCAs are susceptible to acoustic droplet vaporization within these parameters 
[26].
In order to promote cellular internalization, we decorated folate to the PCCA shell in order 
to target folate receptor-alpha (FR-α), which is overexpressed on the surface of breast, 
ovarian, cervical, and colorectal cancer cells and relatively absent from normal tissues [29]. 
Previous studies have shown that folate receptor overexpression is associated with worse 
clinical outcomes in breast cancer patients [30, 31]. Hartmann et al. showed that 81% of 
breast tumors with strong FR-α expression recurred, compared to 38% recurrence for 
tumors with weak FR-α expression [31]. Necela et al. demonstrated that FR-α 
overexpression is associated with increased folate uptake and increased growth of breast 
cancer cells [32], implying FR-mediated folate uptake as a potential tumor-promoting 
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mechanism. The association between FR-α overexpression and poor prognosis suggests that 
FR-targeting can be used to detect or treat high-risk breast tumors.
In addition to its affordability, the folate ligand is an appealing avenue for targeted delivery 
due to its high binding affinity and internalization frequency for the folate receptor [33]. The 
two breast cancer cell lines analyzed in this study were MDA-MB-231 and MCF-7, both of 
which express folate receptor, although MDA-MB-231 cells express FR-α to a greater extent 
than MCF-7 cells [34, 35]. Recent efforts to quantify folate receptor isoform expression on 
the surface of breast cancer cells has shown that MDA-MB-231 cells have 1.76 times more 
FR-α expression relative to MCF-7 cells [35]. Folate receptor-targeted nanoparticles have 
been investigated for magnetic resonance imaging [34] and photoacoustic imaging [36] of 
breast tumors. In addition to imaging agents, targeted nanoparticles can deliver gene vectors 
or drugs to cancer cells, thereby maximizing the therapeutic payload and limiting off-target 
effects. Folate receptor-targeted nanovehicles have been used to deliver siRNA [37] and 
chemotherapeutic drugs [38, 39, 40, 41, 42] intracellularly within MDA-MB-231 and 
MCF-7 breast cancer cells. Nanoparticles ranging from 50 – 400 nm are capable of folate 
receptor-mediated endocytosis [36, 37, 40, 44], which overlaps with the sizing distribution 
of our 1:1 DFB/OFP nanodroplet formulation used in the present study [26]. For both MDA-
MB-231 and MCF-7 breast cancer cells, one hour has proven sufficient for intracellular 
accumulation of nanoparticles via the folate receptor pathway [34, 36].
Following folate receptor-mediated nanoparticle uptake by cancer cells, ultrasound has been 
used to trigger drug release from eLiposomes [43] or polymersomes [44]. However, the 
ultrasound PCCA platform has not yet been applied for targeted molecular imaging of breast 
cancer. In this in vitro proof-of-principle study, we provide evidence of folate receptor-
mediated intracellular delivery and ultrasonic activation of PCCAs using breast cancer cells.
2. Materials and Methods
2.1 Tissue Culture
Human breast cancer cell lines MDA-MB-231 and MCF-7 (obtained from the Experimental 
Mouse Shared Services at The University of Arizona Cancer Center) were cultured in 
RPMI-1640 Medium and Dulbecco’s Minimum Eagle Medium, respectively, supplemented 
with 10% fetal bovine serum and 1% antibiotics (100 µg/mL penicillin-streptomycin). The 
cells were grown in 75 cm2 culture flasks (Sarstedt, Numbrecht, Germany) and maintained 
at 37 °C in an incubator containing 5% CO2. Two days prior to confocal imaging, cells were 
plated on a 50 mm diameter circular d-polylysine coated culture dish with a No. 1.5 
coverslip attached over a small hole in the bottom dish (MatTek Corp., Ashland, MA). At 
the time of imaging, cells were roughly 40 – 60% confluent across the coverslip.
2.2 PCCA Formulation
PCCA sample preparation has been adapted from previously described literature methods 
[45], with the following modifications and clarifications. The lipid coat was prepared as a 
colloidal dispersion by dissolving a 9:1 ratio of dipalmitoylphosphatidylcholine (DPPC) and 
1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-{methoxy(polyethylene 
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glycol)-2000] (DPPE-PEG-2000) (Avanti Polar Lipids, Alabaster, AL) in a solution of 
normal saline, propylene glycol, and glycerol (16:3:1, v:v) for a total lipid concentration of 1 
mg/mL. The lipids were first dissolved in propylene glycol by heating to approximately 
60 °C. Once dissolved, normal saline was slowly added, and heating was maintained until 
the lipid colloid remained opalescent in appearance. Finally, the remaining glycerol was 
added with heating so as to maintain the opalescent appearance.
For the FR-targeted PCCA formulation, folate bioconjugate ligand (Avanti Polar Lipids, 
Alabaster, AL) (Figure 2) was added to the lipid emulsion at a concentration of 2 mol %. 
Untargeted PCCAs were formulated without folate incorporation. A volume of 1.5 mL of 
the lipid mixture was added to a 3 mL glass vial (Wheaton Industries, Millville, NJ), and 
1,1’-dioctadecyl-3,3,3’,3’- tetramethylindocarbocyanine perchlorate (DiI, Invitrogen, 
Eugene, OR) was added to the lipid mixture at a concentration of 2 µg/mL in order to 
fluorescently stain the lipid shell of the PCCAs. The vial was then stoppered and crimped. 
The vial was purged with 50 mL of a 1:1 mixture of decafluorobutane (DFB) / 
octafluoropropane (OFP) gases (Fluoromed, Round Rock, TX) via an 18 Gauge needle 
introduced into the vial septum, along with a vent needle. Mechanical agitation for 45 
seconds using a Vialmix™ shaker (Bristol-Myers-Squibb, New York, NY) was sufficient for 
inducing the formation of stable, microscale bubbles composed of a gaseous perfluorocarbon 
core encapsulated by a folate-decorated lipid shell.
In order to condense microbubbles into nanodroplets, the headspace of the vial was 
pressurized according to previously described literature methods [45]. Using a 60 mL 
syringe and an 18 Gauge needle, 30 mL of room air was compressed into the vial septum 
while the vial was immersed in an ice-salt bath (−7 °C to −10 °C). A near complete 
disappearance of large bubbles and a change in the consistency of the PCCA solution 
indicated successful microbubble condensation. The PCCA solution was kept in the ice-salt 
bath for 15 minutes to promote nanodroplet formation and stability. PCCA formulations 
were prepared immediately prior to each individual imaging experiment, such that 
condensation of microbubbles into nanodroplets preceded incubation with cells by 15 – 20 
minutes.
2.3 Confocal Microscopy
Prior to adding PCCAs to the breast cancer cells, 5 µL of Calcein AM dye (Life 
Technologies, Grand Island, NY) was added to 5 mL media in the tissue culture dish in order 
to cytoplasmically stain all living cells. Next, 100 µL of PCCA formulation was added to the 
media in the dish, and cells were incubated at 37 °C for 1 hour. In addition to imaging with 
FR-targeted PCCAs and untargeted PCCAs, control experiments were performed in which 3 
µL DiI (no PCCAs) was added to calcein-stained live cells. Following incubation, media was 
aspirated and cells were washed with PBS three times to remove any unbound PCCAs from 
the culture dish. The dish was refilled with 5 mL media for imaging.
One hour prior to imaging, the environmental chamber on the Leica SP5 confocal 
microscope (Arizona Cancer Center Cancer Imaging Shared Resources) was equilibrated to 
37 °C to maintain the live cells for the duration of imaging. An argon 488 nm laser was used 
to detect calcein (λexcitation = 495 nm, λemission = 516 nm), and a HeNe 543 nm laser was 
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used for DiI (λexcitation = 549 nm, λemission = 565 nm). All confocal images were collected 
using a 63× oil-immersion objective. Z-stacks were obtained as 1-micron sections over a 10 
– 12 micron range. Cells were imaged before the application of ultrasound as a baseline. 
Acoustic activation was achieved using a portable ultrasound unit (ZONARE Medical 
Systems, Mountain View, CA) with a center US frequency of 9 MHz and a frame rate of 13 
Hz. The mechanical index of the acoustic pulse was set to 1.0 or 1.5. The ultrasound 
transducer was immersed in the culture media and scanned across the dish twice for a total 
exposure time of 6 seconds. Cells were then imaged immediately after ultrasound exposure.
2.4 Image Analysis and Quantification
Images were analyzed using the LAS AF software that accompanied the Leica SP5 confocal 
microscope. One culture dish represents one experiment (n = 1), and six experiments (n = 6) 
were performed for each of the four experimental groups (MDA-MB-231 at MI = 1.0, 
MDA-MB-231 at MI = 1.5, MCF-7 at MI = 1.0, MCF-7 at MI = 1.5). For each culture dish, 
images were obtained for 3 – 6 random fields pre-ultrasound and 3 – 6 random fields post-
ultrasound. Entire regions of cells were chosen at random regardless of whether 
microbubbles were present or absent. The entire ensemble of cells was assessed for 
fluorescently labeled microbubbles, and the average number of microbubbles present per cell 
was determined both before and after ultrasound activation. Intracellular microbubbles were 
identified by a circular DiI+ signal (red) that colocalizes with a) a void in the calcein channel 
and/or b) a bubble in the transmitted light channel. Within the image processing software, all 
microbubble diameters were manually sized with the software sizing tool. For each dish 
(pre- and post-US), the proportion of cells with intracellularly activated microbubbles was 
determined. For all cells with at least 1 intracellular microbubble, the mean number of 
microbubbles per cell was calculated. Percent internalization and number of intracellular 
microbubbles per cell values are depicted as mean ± standard error (SE) of the mean. All 
reported p-values are two-sided.
3. Results
3.1 MDA-MB-231 Imaging
Confocal microscopy imaging of MDA-MB-231 breast cancer cells in vitro demonstrated 
consistent observation of intracellular microbubbles, as evidenced by a red DiI+ signal 
(Figure 3B) colocalized with a void in the calcein channel (Figure 3A) and/or a bubble in the 
transmitted light channel (Figure 3C). In total, 1,334 MDA-MB-231 cells were imaged. 
After the application of ultrasound with MI = 1.0, FR-targeted PCCAs were observed 
intracellularly in 93.0% ± 2.7% (Mean ± SE) of MDA-MB-231 cells at a rate of 4.38 ± 0.98 
(Mean ± SE) microbubbles per cell (Table 1). Parallel MDA-MB-231 imaging experiments 
were performed at MI = 1.5, with all other conditions held constant. After applying acoustic 
energy with MI = 1.5, FR-targeted PCCAs were detected intracellularly in 79.5% ± 6.8% 
(SE) of MDA-MB-231 cells at a rate of 3.63 ± 0.67 (SE) microbubbles per cell (Table 1).
It should be noted that microbubbles were observed intracellularly prior to the application of 
ultrasound, indicating a thermal component of PCCA activation prior to acoustic droplet 
vaporization. Before applying ultrasound to MDA-MB-231 cells, FR-targeted microbubbles 
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were detected intracellularly in 55.2% ± 7.5% (SE) of all cells combined across both 
acoustic conditions. However, it was clear that after insonation, the proportion of MDA-
MB-231 cells with intracellular microbubbles increased significantly (p < 0.01) relative to 
pre-ultrasound data. The ratio of intracellular microbubbles observed post-ultrasound / pre-
ultrasound was 1.90 ± 0.32 (SD) using MI = 1.0 and 1.97 ± 0.22 (SD) at MI = 1.5.
In order to confirm that PCCA internalization was occurring via folate receptor-mediated 
endocytosis, control experiments were conducted using untargeted PCCAs. With all other 
parameters held constant, PCCAs were formulated without the folate ligand. Confocal 
imaging of MDA-MB-231 cells using untargeted PCCAs revealed that nonspecific, 
untargeted uptake of nanodroplets occurs to a minor extent. On average, untargeted PCCAs 
were observed intracellularly in 4.4% ± 3.0% (SE) of MDA-MB-231 cells after applying 
ultrasound (Figure 3e). Folate incorporation increased the frequency of intracellular 
microbubble observation by a factor of roughly 45 compared to untargeted PCCAs. Because 
folate-decorated PCCAs demonstrated significantly greater uptake than untargeted PCCAs 
(p < 0.0001), this was strong evidence that intracellular PCCA delivery was primarily folate 
receptor-mediated.
3.2 MCF-7 Imaging
Utilizing the same FR-targeted PCCA formulation, MCF-7 breast cancer cells were imaged 
to assess intracellular PCCA delivery and activation. In total, 1,525 MCF-7 cells were 
analyzed. FR-targeted PCCAs were consistently detected intracellularly within MCF-7 cells 
(Figure 4), albeit significantly less than was observed using MDA-MB-231 cells (p < 0.001). 
After the application of ultrasound with MI = 1.0, FR-targeted PCCAs were observed 
intracellularly in 42.4% ± 5.0% (SE) of MCF-7 cells at a rate of 1.72 ± 0.07 (SE) 
microbubbles per cell (Table 1). For the corresponding MCF-7 imaging experiments using 
MI = 1.5, FR-targeted PCCAs were detected intracellularly in 35.7% ± 6.8% (SE) of cells at 
a rate of 2.32 ± 0.27 (SE) microbubbles per cell (Table 1).
As was observed during MDA-MB-231 imaging, there were PCCAs vaporized 
intracellularly within MCF-7 cells before applying ultrasound. Prior to insonation, FR-
targeted microbubbles were detected intracellularly in 28.6% ± 3.8% of all MCF-7 cells. 
Applying acoustic energy with MI = 1.0 increased the frequency of intracellular PCCA 
observation by a factor of 1.81 ± 0.35 (SD), which indicates that ultrasound at MI = 1.0 
significantly amplifies PCCA activation (p < 0.01). For the MCF-7 imaging experiments at 
MI = 1.5, ultrasound application enhanced intracellular PCCA activation by a factor of 1.37 
± 0.35 (SD) (p = 0.164).
Control MCF-7 imaging experiments using untargeted PCCAs were performed to quantify 
nonspecific uptake in comparison to folate receptor-mediated nanoparticle delivery. Without 
folate incorporation, untargeted PCCAs were observed intracellularly in 8.0% ± 1.0% of 
MCF-7 cells after insonation (Figure 4e). Decorating the PCCA shell with folate enhanced 
intracellular delivery significantly (p < 0.001). FR-targeted PCCAs were observed 
intracellularly 8.27 (MI = 1.0) and 5.54 (MI = 1.5) times as frequently as untargeted PCCAs.
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3.3 Sizing of Intracellular Microbubbles
Every microbubble detected via microscopy was manually sized with the aforementioned 
LAS AF software. Across both cell lines, 5,346 microbubbles were identified and sized. 
Microbubbles observed intracellularly ranged from 500 nm – 6 microns with a skewed right 
distribution (Figure 5). For MDA-MB-231 imaging experiments, intracellular microbubbles 
had a mean diameter of 1.09 ± 0.44 (SD) microns with an interquartile range (IQR: defined 
as the middle 50% of all intracellular microbubble sizes residing between the 25th and 75th 
percentile) of 0.82 – 1.24 microns (Figure 5). For MCF-7 imaging experiments, the mean 
size of intracellular microbubbles was 1.29 ± 0.86 (SD) microns with IQR = 0.84 – 1.48 
microns (Figure 5).
3.4 Extracellularly Bound Microbubbles
Although the majority of microbubbles were detected intracellularly (93.0% of all MBs 
observed intracellularly vs. 7.0% extracellularly), there was significant detection of large 
extracellularly bound microbubbles across both cell lines. Before applying ultrasound, 
extracellularly bound microbubbles were relatively absent, detected on the surface of less 
than 1% of all cells. After insonation, microbubbles were observed on the surface of 16.3% 
of MDA-MB-231 cells and 9.5% of MCF-7 cells. Triplicate PBS washes after the 1-hour 
incubation period, prior to imaging, ensured that any PCCAs observed extracellularly were 
bound to surface folate receptors, not simply floating in solution. Extracellular microbubbles 
ranged from 1 – 100 microns (IQR = 2.2 – 28.3 microns) with a median diameter of 8.7 
microns.
4. Discussion
To the best of our knowledge, this is the first demonstration of intracellular delivery and 
ultrasound-stimulated activation of phase-change contrast agents (PCCAs) targeted to cancer 
cells. By arming the DPPC / DPPE-PEG lipid shell with folate, we successfully targeted 1:1 
DFB/OFP PCCAs to overexpressed folate receptors on the surface of MDA-MB-231 and 
MCF-7 breast cancer cells. For both cell lines, one hour of incubation proved adequate for 
PCCA binding and folate receptor-mediated endocytosis.
The unique capabilities of confocal microscopy facilitated reliable intracellular microbubble 
detection and quantification within live breast cancer cells in vitro. The microscope’s Z-
stack imaging sequence scans the entire three-dimensional volume of each cell, producing 
fluorescent images that three-dimensionally map DiI+ microbubbles (red) within or outside 
the calcein+ cytoplasmic regions (green). The intensity and quality of DiI and calcein signals 
varied between and within samples, but the requirements for positively identifying an 
intracellular microbubble were held constant: red DiI+ ring (Figure 4B) colocalized with a) 
void in calcein channel (Figure 4A) and/or b) identifiable bubble in the transmitted light 
channel (Figure 4C).
For both MDA-MB-231 and MCF-7 cell lines, control experiments incubating with DiI only 
(no PCCAs) produced no intracellular DiI+ signals (data not included). These results 
eliminate the possibility that DiI stains intracellular organelles or forms micelles that 
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internalize. Thus, we verified that any DiI+ rings observed intracellularly are in fact 
associated with the lipid coat of a PCCA.
Presently, there have been multiple promising Phase II clinical trials using folate receptor-
targeted chemotherapeutic agent vintafolide in combination with FR-targeted companion 
SPECT imaging agent (99m)Tc-etarfolatide for the treatment of ovarian cancer [46, 47]. 
However, our study may be the first to examine FR-mediated intracellular uptake and 
activation of a phase-change contrast agent.
Folate receptor-targeted PCCAs were observed intracellularly within both breast cancer cell 
lines, but cellular uptake was significantly greater for MDA-MB-231 cells (p < 0.001). The 
increased intracellular accumulation of FR-targeted PCCAs in MDA-MB-231 cells (93.0% 
internalization at MI = 1.0, 79.5% at MI = 1.5) compared to MCF-7 cells (42.4% 
internalization at MI = 1.0, 35.7% at MI = 1.5) coincides with FR-α expression profiles. 
MDA-MB-231 cells strongly overexpress FR-α, while FR-α expression is moderate on the 
surface of MCF-7 cells [34, 35]. Using folate receptor-targeted gold nanoparticles 
conjugated with doxorubicin, Banu et al. showed that cellular destruction was greater in 
MDA-MB-231 cells than MCF-7 cells, a reflection of more efficient uptake [39]. Similarly, 
Meier et al. demonstrated that folate receptor-mediated uptake of iron oxide nanoparticles 
was significantly greater for MDA-MB-231 cells than MCF-7 cells [34]. It is also possible 
that other factors, such as the efficiency of endocytosis pathways and passive diffusion 
mechanisms as well as the expression of other surface receptors, could contribute to the 
observed difference in PCCA uptake to a minor extent.
Folate receptor-mediated endocytosis was the primary means of PCCA internalization, as 
indicated by imaging experiments utilizing untargeted PCCAs. Without folate incorporation, 
roughly 2 – 10% of breast cancer cells showed evidence of intracellular PCCA activation. 
These results show that nonspecific uptake can occur; however, it occurs infrequently 
compared to MCF-7 FR-mediated endocytosis (p < 0.001) and even less frequently 
compared to MDA-MB-231 FR-mediated endocytosis (p < 0.0001). The increased 
selectivity of FR-targeted PCCAs toward MDA-MB-231 cells (45-fold greater 
internalization for FR-targeted vs. untargeted) compared to MCF-7 cells (7-fold greater 
internalization for FR-targeted vs. untargeted) is notably in agreement with FR-α expression 
profiles. FR-α overexpression is greater in the MDA-MB-231 cell line than the MCF-7 cell 
line [34, 35]. Thus, as is consistent with previous literature [34, 39], the uptake-promoting 
effect of folate decoration is more pronounced when imaging MDA-MB-231 cells.
Other folate receptor-targeted nanoparticles have shown similar evidence of untargeted 
uptake occurring in addition to FR-mediated delivery. Chen et al. used FR-targeted PLGA 
nanoparticles to deliver the drug vincristine sulfate intracellularly to MCF-7 cells, and folate 
incorporation enhanced cytotoxicity by a factor of 1.52 times relative to untargeted 
nanoparticles carrying the drug [42]. Using MCF-7 cells, Balasundaram et al. showed that 
folate-armed conjugated polymer nanoparticles produced a photoacoustic signal 5 times that 
of untargeted nanoparticles [36], which is similar to our MCF-7 data. Utilizing alginate-
peptide amphiphile core-shell microparticles to deliver doxorubicin to MDA-MB-231 cells 
in vitro, Boekhoven et al. demonstrated that FR-targeted microparticles produced 60 times 
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greater cytotoxicity compared to untargeted microparticles [48]. Our MDA-MB-231 imaging 
showed that folate incorporation increased the frequency of intracellular PCCA detection by 
roughly 45 times. On the whole, folate receptor targeting appears more favorable for MDA-
MB-231 cells than MCF-7 cells, consistent with previous FR-targeted experiments.
The skewed right sizing distribution of intracellular microbubbles (Figure 5) is consistent 
with previously published sizing data for perfluorocarbon bubbles [19, 24, 26]. The average 
intracellular microbubble size was 1.09 ± 0.44 (SD) microns for MDA-MB-231 cells and 
1.29 ± 0.86 (SD) microns for MCF-7 cells (Figure 5). Using the same 1:1 DFB/OFP 
perfluorocarbon composition that we employ in the present study, Sheeran et al. described 
an average microbubble size of 1.02 ± 0.64 (SD) microns with a skewed right distribution 
due to large outlier bubbles [26]. Thus, the intracellular microbubble size distribution from 
our in vitro study is consistent with the original size distribution profiles from ultrasound-
activated PCCAs in solution. The agreement between our weighted distribution of 
intracellular microbubble sizes (Figure 5) and Sheeran’s sizing data [26] indicates that in 
vitro incubation delivers a population of nanodroplets intracellularly capable of yielding 
microbubbles with sizes similar to microbubbles in solution. It was valuable to ascertain that 
PCCA condensation, cellular internalization, and vaporization do not substantially alter the 
distribution of microbubble sizes.
Without directly sizing precursor nanodroplets, the size range of 1:1 DFB/OFP nanodroplets 
was inferred to lie between 100 – 600 nm, as was previously shown by our group [26]. 
According to the literature, the maximum nanoparticle size for folate receptor-mediated 
endocytosis is 400 nm [40, 44]. Assuming approximately 6× volumetric expansion ratio for 
acoustic droplet vaporization of 1:1 DFB/OFP PCCAs [49, 50], the IQR of intracellularly 
detected microbubbles (800 nm – 1.5 microns) indicates that the plurality of PCCAs were 
internalized as nanodroplets ranging from 150 – 250 nm. The smallest intracellular bubbles 
(500 – 800 nm) likely originated from the vaporization of the smallest nanodroplets (100 – 
150 nm). Although the majority of intracellular microbubbles observed were less than 2 
microns in diameter, there was occasional detection of larger microbubbles, including some 
as big as 4 – 6 microns (Figure 5). This population of intracellular microbubbles (2 – 6 
microns) may be a product of the largest internalized nanodroplets (250 – 400 nm) and 
possibly a function of post-vaporization expansion via gas absorption that has been 
previously described [24].
The appearance of large, extracellularly bound microbubbles after insonation seems to 
support the concept that there is a maximum nanoparticle size for FR-mediated endocytosis. 
Of all microbubbles observed, 7.0% were detected extracellularly (median diameter = 8.7 
microns). The IQR of extracellular microbubble sizes (2.2 – 28.3 microns) varied 
significantly (p < 0.001) from the IQR of intracellular microbubbles (800 nm – 1.5 microns). 
Therefore, we hypothesize that extracellular PCCAs are evidence of large outlier 
nanodroplets (larger than 400 nm) that bind to FR-α yet remain restricted to the extracellular 
surface. From previously published sizing data for 1:1 DFB/OFP nanodroplets, there is a 
significant population of droplets larger than 400 nm [26], in other words too large for FR-
mediated uptake. Because droplets larger than 400 nm cannot be internalized via FR-
mediated endocytosis, these PCCAs are vaporized extracellularly. The polydisperse 
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distribution of extracellular microbubbles is of marginal consequence for in vivo 
applications because large outlier PCCAs (droplets larger than 600 nm) cannot escape the 
vasculature. Nevertheless, methods to selectively eliminate large outlier PCCAs should still 
be considered for future studies. For example, Seo et al. employed microfluidics and a co-
solvent approach to control the sizes of perfluorocarbon nanodroplets [51]. Additional 
methods such as decantation or filtration may be sufficient to eliminate these outliers [28].
Prior to insonation, intracellular microbubbles were detected in approximately 25 – 30 % of 
MCF-7 cells (Figure 4E) and 50 – 60 % of MDA-MB-231 cells (Figure 3E). The pre-
ultrasound detection of intracellularly activated microbubbles can likely be attributed to the 
vaporization of internalized nanodroplets due to thermal activation. Although 1 hour was 
provided for PCCA binding and internalization, some literature reports have indicated that 
folate receptor-mediated nanoparticle uptake can occur in 5 – 10 minutes in vitro [52]. Thus, 
it is possible that a nanodroplet internalized in 10 minutes could lie dormant intracellularly 
for 1 hour or more before pre-ultrasound imaging. In previously published work from our 
group, we evaluated the stability of low-boiling perfluorocarbon PCCAs over time. After 1 
hour at 37 °C (same temperature used during incubation and imaging for this study), the 
concentration of 1:1 DFB/OFP nanodroplet samples decreased by 45% due to thermal 
instability [26]. This seems to support the pre-ultrasound PCCA vaporization observed in 
our in vitro breast cancer imaging study. For future explorations, implementing a less 
volatile perfluorocarbon mixture that reduces PCCA thermal vaporization may prove 
valuable. Experiments are in progress using 100% decafluorobutane (DFB, C4F10) and 
mixtures of DFB and dodecafluoropentane (DDFP, C5F12). We do not anticipate PCCA 
thermal vaporization being overly problematic for in vivo applications because thermally 
activated PCCAs would likely be intravascular, not extravascular, bubbles that will never 
reach breast cancer tissue due to size constraints.
The mechanical index of ultrasound application was varied in order to determine the 
vaporization threshold for 1:1 DFB/OFP PCCAs intracellularly. For both breast cancer cell 
lines, it appears that a mechanical index of 1.0 is sufficient for triggering the vaporization of 
1:1 DFB/OFP PCCAs. It must be noted that application of ultrasound was solely for the 
purposes of activation of internalized PCCAs, while the occurrence of intracellular PCCAs 
was a function of folate receptor-mediated internalization. Across both cell lines, insonation 
increased the frequency of intracellular PCCA detection, indicating that ultrasound amplifies 
the extent of PCCA activation. Ultrasound application significantly increased the occurrence 
of PCCA vaporization (p < 0.01) in three (MDA-MB-231 at MI = 1.0 and 1.5, MCF-7 at MI 
= 1.0) out of four experimental groups (Table 1). For the MCF-7 group at MI = 1.5, there 
were more intracellular microbubbles observed after ultrasound activation (Activation Ratio 
= 1.37 ± 0.35), however the result was insignificant (p = .164). Stabilizing the 
perfluorocarbon mixture and increasing ultrasound exposure time should augment the effect 
of ultrasonic activation relative to thermal activation. For future studies involving different 
perfluorocarbon compositions, reassessment of the acoustic activation parameters may prove 
useful.
With an estimated 40,000 deaths from invasive breast cancer in the United States in 2016 
[1], novel methods of early detection and therapy are necessitated. By providing evidence 
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for the intracellular delivery and activation of folate receptor-targeted PCCAs in breast 
cancer cells in vitro, we hope to expand the scope of exploratory investigation and clinical 
potential of ultrasound theranostics for breast cancer. For the most part, ultrasound 
theranostic applications for cancer have remained limited to the vasculature [9, 10, 53, 54], 
yet the PCCA concept studied herein offers a platform toward extravascular imaging and 
therapy. Soon, we hope to expand our research to in vivo ultrasound imaging of breast 
cancer tumors in mice.
In addition to intracellular imaging with PCCAs, alternative modes of drug delivery and 
cellular ablation are possible by manipulating the acoustic parameters to induce microbubble 
cavitation. Using dodecafluoropentane (DDFP) emulsion-loaded liposomes targeted to 
MCF-7 cells, Ninomiya et al. provided evidence for ultrasound-mediated cell rupture, 
resulting in 43% cell viability after insonation [55]. Conjugation of a nuclear localization 
sequence [56] to the PCCA shell can promote migration of intracellular nanoparticles to the 
nucleus, thereby maximizing ultrasound-mediated therapeutic effects. Although PCCA 
research remains in its early stages, we are hopeful that the data presented in this study 
facilitates a new outlook on ultrasound molecular imaging and therapy.
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PCCA phase-change contrast agent
US ultrasound
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PFC perfluorocarbon
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OFP octafluoropropane
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MI mechanical index
FR folate receptor
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Figure 1. 
Schematic illustration of in vitro breast cancer imaging: (1) Liquid perfluorocarbon phase-
change contrast agents (PCCAs) added directly to culture medium for 1-hour incubation. (2) 
Folate-decorated PCCAs bind to folate receptors overexpressed on the surface of breast 
cancer cells. (3) PCCA nanodroplets internalize via folate receptor-mediated endocytosis. 
(4) Ultrasound pulse triggers phase-shift from liquid nanodroplets to gaseous microbubbles. 
(5) Intracellularly activated microbubbles imaged via confocal microscopy.
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Figure 2. 
Chemical structure of the folate targeting construct: 1,2-distearoyl-sn-glycero-3-
phosphoethanolamine-N-[folate(polyethylene glycol)-2000] (ammonium salt) (DSPE-
PEG(2000) Folate)
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Figure 3. 
MDA-MB-231 intracellular imaging, with top row (A–D) depicting 7 FR-targeted PCCAs 
activated intracellularly after insonation at MI = 1.0 (A) Calcein stains the cytoplasm of 
living cells. (B) DiI stains the lipid shell of PCCAs. (C) Transmitted light channel shows 
bubble-like structures intracellularly. (D) All three channels overlaid shows the 
colocalization of DiI+ / calcein- regions. (E) Graph depicts the proportion of MDA-MB-231 
cells (mean +/− SE) with at least 1 intracellularly activated microbubble before (left, light 
gray) and after (right, dark gray) ultrasound application.
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Figure 4. 
MCF-7 intracellular imaging, with top row (A–D) depicting 3 intracellular FR-targeted 
PCCAs after insonation at MI = 1.5 (A) Cytoplasmic stain calcein shows 3 circular voids. 
(B) DiI stains the lipid shell of PCCAs. (C) Transmitted light channel shows 3 bubbles 
intracellularly. (D) All three channels overlaid shows the colocalization of DiI+ / calcein- 
bubble regions. (E) Graph depicts the proportion of MCF-7 cells (mean +/− SE) with at least 
1 intracellularly activated microbubble before (left, light gray) and after (right, dark gray) 
ultrasound application.
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Figure 5. 
Sizing of intracellular microbubbles (MBs) detected within MDA-MB-231 cells (left, blue) 
and MCF-7 cells (right, red)
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Table 1
Summary statistics for MDA-MB-231 (n = 6 at MI = 1.0, n = 6 at MI = 1.5) and MCF-7 (n = 6 at MI = 1.0, n 
= 6 at MI = 1.5) imaging experiments. (i) % Internalization = percentage of cells with at least 1 intracellular 
microbubble. (ii) # MB per cell = mean number of microbubbles per cell, for all cells with at least 1 
intracellular microbubble. (iii) Ultrasound Activation Ratio = number of intracellular microbubbles per cell 
post-ultrasound / number of intracellular microbubbles per cell pre-ultrasound, including those cells with 0 
intracellular PCCAs. (iv) FR-α Targeting Ratio = number of FR-targeted intracellular microbubbles per cell / 
number of untargeted intracellular microbubbles per cell, including those cells with 0 intracellular PCCAs.
Cell Line MDA-MB-231 MCF-7
Mechanical Index MI = 1.0 MI = 1.5 MI = 1.0 MI = 1.5
i) % Internalization (± SE) 93.0% ± 2.7% 79.5% ± 6.8% 42.4% ± 5.0% 35.7% ± 6.8%
ii) # MB per cell (± SE) 4.38 ± 0.98 3.63 ± 0.67 1.72 ± 0.07 2.32 ± 0.27
iii) Ultrasound Activation
Ratio (± SD)
1.90 ± 0.32
(p < 0.01)
1.97 ± 0.22
(p < 0.01)
1.81 ± 0.35
(p < 0.01)
1.37 ± 0.33
(p = 0.164)
iv) FR-α Targeting Ratio 44.8
(p < 0.0001)
48.5
(p < 0.0001)
8.27
(p < 0.001)
5.54
(p < 0.001)
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